Case Studies
Gilmartin Group offers a comprehensive suite of advisory services to support our clients in achieving a variety of goals or overcoming specific challenges. Below are select healthcare IR case studies that highlight the results of our public and private company advisory, exemplifying investor relations best practices in action.
Strategic Investor Relations
Street Visibility for Public Company Updated Clinical Strategy
Client A is a SMID-cap clinical-stage oncology company with a drug candidate with a novel mechanism of action...
Public Company FP&A and Guidance Support
Public Company underperformed internal financial projections leading to a reduction in guidance, stock price underperformance, increased shareholder turnover. As a result, management had increased IR...
IPO Advisory
Strategic Advisor on Kestra Medical’s $232M Initial Public Offering
Kestra Medical Technologies (NASDAQ: KMTS) priced its $232M IPO on March 5, 2025. The upsized, double-digit oversubscribed IPO priced above the initial range and closed nearly 30% above...
Strategic Advisor on Ceribell’s $207M Initial Public Offering
Ceribell (NASDAQ: CBLL) priced its $207M initial public offering on October 10, 2024. The upsized, double-digit oversubscribed IPO priced above the initial pricing range and traded up ~47% on the first day...
European Listed Life Science Tools U.S. IPO
Company A was founded over 20 years ago and listed on the London Stock Exchange-AIM in 2016. Gilmartin Group was retained to advise on syndicate selection, IPO material preparation including S1...
Private Company Fundraising
Private Company Series C Raise: Commercial Stage Diagnostics Company
Client A is a private diagnostics company focused on developing diagnostic tests for the advancement of gastrointestinal health. Their FDA-approved test, used in combination with leading industry PCR in...
Private Company Series C Fundraise
Through strategic introductions and close advisory support of the Gilmartin team, the Series C raise was completed successfully in October of 2021 in two tranches with 9 new investors...
Shareholder Engagement
KOL Event for Analysts and Investors
A publicly-traded Gilmartin Group client was working to cultivate additional interest from both analysts and investors in its story, including its progress to expand its clinical use cases and start recognizing revenue...